Exploring foci of
2025-03-28
Second line advanced or metastatic non-small cell lung cancer treatment after chemo-immunotherapy: a retrospective study
2025-03-28 • Lyudmila Bazhenova, Beilei Cai, Danielle Gentile, Jonathan Kish, Bruce A. Feinberg
rwPFS and OS were consistent with clinical trials of 2L IO regimens. The few patients who received IO in 1L and 2L had favorable rwPFS and OS. Future research on sequential IO therapies in 1L and 2L aNSCLC is warranted.
Stena Line
Second Act (Film)
Second Voyage Of James Cook
Glastonbury Festival Line-Ups
Second Anglo-Sikh War
Simplified Molecular Input Line Entry System
Advanced Format
Overhead Line
On The Line (Jenny Lewis Album)
Exploring foci of
2025-10-15
Drought-Induced Epigenetic Memory in the cambium of Poplar Trees persists and primes future stress responses
2025-10-15 • Alexandre Duplan, Yu Feng, Gwenvael LASKAR, Beilei Cai, Vincent Segura, Alain Delaunay, Ian Jan, Christian Daviaud, A. Toumi, Françoise Laurans, Ma...
Abstract Understanding how perennial plants such as trees perceive, integrate and memorize environmental stresses like water deficit is crucial in the context of climate change. We investigated short-term and transannual memory of water deficit in cambium derived tissues of poplars ( Populus spp .) using two contrasting genotypes and four genetically modified epitypes with altered DNA methylation machinery. We found persistent changes in hormone profiles, gene expression and DNA methylation one week after stress r…
A Memory Of Light
Computer Memory
Bright Memory
Static Random-Access Memory
Memory Of Mankind
Flash Memory
Long Short-Term Memory
Nonvolatile Bios Memory
Non-Uniform Memory Access
Exploring foci of
2024-04-17
Effectiveness of standard treatments in non-small-cell lung cancer with METexon14 skipping mutation: a real-world study
2024-04-17 • Muhammad Furqan, Siddharth Karanth, RK Goyal, Beilei Cai, Julien Rombi, Keith L. Davis, Nydia Caro, Teddy Saliba
<b>Aim:</b> To assess real-world clinical outcomes with standard therapies for advanced non-small-cell lung cancer (aNSCLC) with METexon14 skipping mutation (METex14).<b>Methods:</b> In an oncologists-led retrospective review of medical records, data were abstracted and analyzed for patients initiating first-line (1L) systemic therapy after 1 January 2017.<b>Results:</b> In total 287 aNSCLC patients with METex14, the real-world best overall response rate was 73.4% for capmatinib (n = 146), 68.8% for immunotherapy …
Standard Of Living In The United States
Rim-174 Standard Eram
Industry Standard Architecture
Business Standard
Philippine Standard Time
Standard Form Contract
Standard Drink
Rim-67 Standard
Standard For The Uniform Scheduling Of Medicines And Poisons
Exploring foci of
2023-01-01
Real-world outcomes in non-small-cell lung cancer patients with MET Exon 14 skipping mutation and brain metastases treated with capmatinib
2023-01-01 • Paul K. Paik, RK Goyal, Beilei Cai, Mark Price, Keith L. Davis, Valérie Derrien Ansquer, Nydia Caro, Teddy Saliba
<b>Aim:</b> To assess real-world clinical outcomes in patients with non-small-cell lung cancer with MET exon 14 skipping mutation and brain metastases (BM) who received capmatinib, a recently approved MET inhibitor, in routine US clinical practice. <b>Materials & methods:</b> Patient data were collected using a retrospective medical record review, led by participating oncologists. Eligible patients initiated treatment with capmatinib in any line, after BM diagnosis, between May 2020 and June 2021. Data on real-wor…
Non-Small-Cell Lung Carcinoma
Executive Outcomes
Exploring foci of
2023-02-28
Computational repurposing and preclinical validation of colquhounia root tablets for membranous nephropathy
2023-02-28 • Xia Mao, Kexin Wang, Yudong Liu, Xiao-Hui Su, Anguo Wu, Lin Chen, Jiangrui Wang, Beilei Cai, Yanqiong Zhang, Feng Huang, Na Lin
Current therapeutics of membranous nephropathy (MN) hold dilemmas of limited clinical response rates, high recurrence rate, and unavoidable adverse effects.1 Colquhounia Root Tablet (CRT) is a Chinese patent medicine prepared from the peeled root of Tripterygium hypoglaucum (Lévl.) Hutch (SFDA approval number: Z20027411). Emerging clinical evidence has indicated a potential therapeutic effect of CRT on MN.2, 3 However, the mechanisms of CRT against MN remain unclear. In this study, 585 putative targets of CRT were…
Computational Linguistics
Computational Fluid Dynamics
Computational Creativity
Computational Biology
Computational Mathematics
Computational Physics
Computational Complexity
Computational Neuroscience
Computational Intelligence